radicals
play

RADICALS Radiotherapy and Androgen Deprivation In Combination After Local Surgery MRC PR11, NCIC PR.13 RADICALS 1 TRIAL DESIGN RADICALS

0 downloads 13 Views 1,69 MB Size Report
  1. RADICALS Radiotherapy and Androgen Deprivation In Combination After Local Surgery MRC PR11, NCIC PR.13 RADICALS 1

  2. TRIAL DESIGN RADICALS 2

  3. Trial Principles • Address the 2 most important questions for post-RP patients  Need for, and timing of, post-operative radiotherapy early (adjuvant) deferred (early salvage)  Use and duration of hormone therapy with post-operative RT none (0 months) short (6 months) long (24 months) RADICALS 3

  4. Trial Principles • Currently, there is variation in practice for both RT & hormone therapy • One or the other or both questions may be suitable for most patients at some point RADICALS 4

  5. RT Timing Randomisation Early RT vs deferred RT post-operatively Eligible post-operative patient RT timing RANDOMISATION Early RT Deferred RT (RT for PSA failure) RADICALS 5

  6. Hormone Duration Randomisation Use of hormones with post-operative RT Patient for post-operative RT (either early or deferred RT) Hormone duration RANDOMISATION Radiotherapy Radiotherapy Radiotherapy Alone + 6 months + 2 years hormone therapy hormone therapy RADICALS 6

  7. Randomisations • Patients in Radiotherapy Timing Randomisation can also join the Hormone Duration Randomisation (if and when they have RT) but are not required to do so. • Consent separately to each randomisation • Patients who have not taken part in the Radiotherapy Timing Randomisation may still enter the Hormone Duration Randomisation alone. RADICALS 7

  8. Hormone Duration Randomisation • 2 or 3 way hormone duration randomisation permissible 3 arm randomisation Hormone duration (preferable) RANDOMISATION RT + RT + RT + no HT 6mo HT 2yr HT 2 arm randomisation Hormone duration (none vs short) RANDOMISATION RT + RT + no HT 6mo HT 2 arm randomisation Hormone duration (short vs long) RANDOMISATION RT + RT + 6mo HT 2yr HT RADICALS 8

  9. Outcome Measures Primary • RADICALS-RT: Freedom from distant metastases • RADICALS-HD: Disease-specific survival (death after PCa progression) Secondary • Disease-specific survival (RADICALS-RT) • Freedom from treatment failure • Clinical progression-free survival • Overall survival • Duration of androgen deprivation • Quality of life RADICALS 9

  10. Sample size • RT timing randomisation ~1250 patients • Hormone duration randomisation ~3000 patients • Total >4000 patients RADICALS 10

  11. INCLUSION & EXCLUSION CRITERIA RADICALS 11

  12. Main Entry Criteria All patients must fulfil: • main entry criteria and • criteria relevant to the randomisation(s) they are taking part in Inclusion • Patient has undergone radical prostatectomy • Prostatic adenocarcinoma • Written informed consent RADICALS 12

  13. Main Entry Criteria Exclusion • Bilateral orchidectomy • Prior pelvic radiotherapy • Other active malignancy likely to interfere with protocol treatment or follow-up • Known distant metastases from prostate cancer • Hormone therapy within previous 6 months months • Previous pre-operative hormone therapy for longer than 8 • Any post-operative hormone therapy* * patients joining 6m vs. 2y randomisation in RADICALS-HD may have started hormones before randomisation but please check with trial unit first RADICALS 13

  14. RT Timing Randomisation Inclusion • Post- operative serum PSA ≤0.2ng/ml • Ideally more than 4 weeks and less than 22 weeks after radical prostatectomy • One or more of: • pT3/4 • Gleason 7-10 (biopsy or surgical sample) • Pre- operative PSA ≥10ng/ml • Positive margins Exclusion • Post-operative biochemical failure, defined as EITHER two consecutive rises in PSA and final PSA >0.1ng/ml OR three consecutive rises in PSA • More than 22 weeks since radical prostatectomy RADICALS 14

  15. Hormone Duration Random n Inclusion • Patient due to receive post-operative radiotherapy (early or deferred) Exclusion • PSA >5ng/ml at the time of randomisation RADICALS 15

  16. Information Booklet • RADICALS Patient Information Booklet is distributed to all recruiting centres • Inform patients about treatment choices and the possibility of participating in RADICALS • Give to patients pre-surgery • Contact MRC CTU for as many copies as you want RADICALS 16

  17. Patient Information DVD • One DVD for each randomisation • Complement the RADICALS Patient Information Sheet • Can also be viewed on www.radicals-trial.org RADICALS 17

  18. TREATMENT RADICALS 18

  19. Radiotherapy Timing Randomisation • Patients in the RT Timing Randomisation will be allocated to either:  Early post-operative RT or  Deferred RT • RT will be the same in either situation:  66Gy in 33 fractions over 6.5 weeks or  52.5Gy in 20 fractions over 4 weeks • RT commences 2 months after hormone therapy RADICALS 19

  20. Hormone Duration Randomisation • Patients in the Hormone Duration Randomisation will be allocated to one of the following:  RT alone  RT + 6 months hormone therapy (short-term)  RT + 2 years hormone therapy (long-term) • Protocol section 6 RADICALS 20

  21. Hormone Duration Randomisation Dispensing Hormone therapy: • Centres will use routinely available products (either LHRH agonists or bicalutamide monotherapy) that will be stored and dispensed in the usual way. RADICALS 21

  22. Stopping trial treatments • A patient may stop allocated trial treatment for the following reasons:  Unacceptable toxicity  Intercurrent illness which prevents further treatment  Withdrawal of consent for treatment  Any alteration in the patient’s condition which justifies the discontinuation of treatment in the clinician’s opinion RADICALS 22

  23. Stopping trial treatments • The reason for stopping trial treatment should be communicated to trial staff by written communication. • Unless a patient states otherwise, it should be assumed that consent is given to continue to record trial data. RADICALS 23

  24. Non-trial treatment • Not permitted: Other therapies for prostate cancer prior to disease progression e.g.:  bilateral orchidectomy  oestrogens  cytotoxic chemotherapy • Permitted:  5-alpha reductase inhibitors  soya  selenium  vitamin E RADICALS 24

  25. Co-enrolment • Ideally, patients should not be participating in any other clinical trial of prostate cancer treatment. • However, there are some trials that overlap and fit with RADICALS. • Patients already in these trials could join RADICALS. • Inform trials office of participation RADICALS 25

  26. ASSESSMENT & FOLLOW-UP RADICALS Protocol – section 7 RADICALS 26

  27. Schedule of visits • The scheduling of case report forms (CRFs) have been kept as simple as possible. • Disease-specific survival and overall survival are outcome measures therefore long term follow-up is very important. RADICALS 27

Recommend Documents


chemistry of tropospheric tropospheric oh and ho
Chemistry of tropospheric tropospheric

Acknowledgments: my participation in CITES-2007 is funded by APN Chemistry of

roots
Roots Slide 4 / 180 The symbol for

Slide 1 / 180 Radicals and Rational Exponents Slide 2 / 180 Roots and

radically connected
Radically Connected Learning Radicals

Radically Connected Learning Radicals with Social Media Learning Radicals

just the maths slides number 1 3 algebra 3 indices and
JUST THE MATHS SLIDES NUMBER 1.3

JUST THE MATHS SLIDES NUMBER 1.3 ALGEBRA 3 (Indices and radicals (or

h br br h
. . H Br Br H (radicals) . . H

How is a chemical reaction happening? reaction mechanisms A reaction mechanism

topological radical for banach modules
Topological radical for Banach modules

Topological radical for Banach modules O. Yu. Aristov 2013 General theory

investigation of emission of alkali radicals during
Investigation of emission of alkali

Investigation of emission of alkali radicals during Investigation of emission

the detection of radiation induced radicals from teeth
The detection of radiation induced

JST project No.20 The detection of radiation induced radicals from teeth

on the complexity of computing real radicals of
On the Complexity of Computing Real

On the Complexity of Computing Real Radicals of Polynomial Systems Mohab Safey

oil sands market campaigns
Oil Sands Market Campaigns Bartholomew

Oil Sands Market Campaigns Bartholomew T. Mongoven mongoven@stratfor.com

their ability to fully capture in vivo
their ability to fully capture in vivo

Problem Current approaches are limited in their ability to fully capture in

development
Development By Dr. Walker Objectives

Arresting Prostate Cancer Development By Dr. Walker Objectives The many

is a product designed specifically for people who suffer
is a product designed specifically for

is a product designed specifically for people who suffer from hair loss is a

pitfalls of urology for
Pitfalls of Urology for Undergraduate

David A. Anderson, MD Born in Sioux City, Iowa Pitfalls of Urology for

panel i aliases for compound names
PANEL I: ALIASES FOR COMPOUND NAMES 5

PANEL I: ALIASES FOR COMPOUND NAMES 5 -pregnan-20-ol-3-one -

should the olympics be divided into men s and women s
Should the Olympics be Divided into

Should the Olympics be Divided into Mens and Womens Events? 1 ENGAGE Silent

medifocus inc
Medifocus, Inc. OTCQX: MDFZF TSXV:

Medifocus, Inc. OTCQX: MDFZF TSXV: MFS www.medifocusinc.com Except for

consult presentation
Consult Presentation Laser Hair

Global leader in laser hair loss treatment since 1987 Consult Presentation

musculoskeletal
MUSCULOSKELETAL PA RT I QUESTION #1

MUSCULOSKELETAL PA RT I QUESTION #1 A 63yo fe ma le pre se nts with b o ny

federal law no 88 fl fl federal law no 88 of 12 june 2008
Federal Law No.88- -FL FL Federal

Federal Law No.88- -FL FL Federal Law No.88 of 12 June 2008 of 12 June

seronegative disease
Seronegative Disease Arthur Bankhurst

4/8/13 Approach to Inflammatory Arthritis: Seropositive and Seronegative

post liver transplant intrahepatic cholestasis etiology
Post-liver transplant intrahepatic

Eur opean Rev iew for Med ical and Pharmacol ogical Sci ences 2017; 21 (1